The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Grigorian O.R.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Moskva

Larina A.A.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr" MZ RF, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

The hyperprolactinemia in gynecological practice: etiology, pathogenesis, clinical presentation, diagnosis, treatment

Authors:

Grigorian O.R., Larina A.A., Andreeva E.N., Melnichenko G.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2013;(4): 14‑20

Read: 13135 times

Download PDF (RU)
Contact the author
Table of contents

THE HYPERPROLACTINEMIA IN GYNECOLOGICAL PRACTICE: ETIOLOGY, PATHOGENESIS, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT
THE HYPERPROLACTINEMIA IN GYNECOLOGICAL PRACTICE: ETIOLOGY, PATHOGENESIS, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT

To cite this article:

Grigorian OR, Larina AA, Andreeva EN, Melnichenko GA. The hyperprolactinemia in gynecological practice: etiology, pathogenesis, clinical presentation, diagnosis, treatment. Russian Journal of Human Reproduction. 2013;(4):14‑20. (In Russ.)

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Reproductive health of women with hepa­titis C (literature review and own data). Russian Journal of Human Reproduction. 2025;(1):12-20
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Epidemiological moni­toring of morbidity in pregnant women in the Russian Fede­ration: trends and medi­cal and orga­nizational prerequisites for adju­sting prevention programs at the popu­lation level. Russian Journal of Human Reproduction. 2025;(2):7-16
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
The practice of using medi­cal abortion in the world. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):19-24
Acute kidney injury during pregnancy with favo­rable obstetric and nephrological outcome. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):65-70
Asplenia — a new cause of thro­mbosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76
Modern aspe­cts of gestational diabetes mellitus: defi­nition, risk factors. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):35-41
Clinical case of primary hype­raldosteronism dete­cted during pregnancy: differential diagnosis, neonatal prognosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):98-104
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Abstract:

The hyperprolactinemia is often associated with different menstrual disorders and may be the cause of endocrine infertility in 25-40%. Pregnancy, lactation and stress as well as pituitary and parasellar tumors, some medications, renal failure, hepatic cirrhosis and hypothyroidism can lead to prolactin level elevation. The dopamine agonist therapy (cabergoline and bromocriptine) is recommended for management of hyperprolactinemia. They may be used during pregnancy. The patients with hyperprolactinaemia have a significant chance of normalizing their prolactin levels at menopause. The need of hyperprolactinaemia and microprolactinoma treatment in menopause should be reassessed.

Keywords:

hyperprolactinemia
pituitary tumors
dopamine agonists
pregnancy
menopaus

Authors:

Grigorian O.R.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Moskva

Larina A.A.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr" MZ RF, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Dedov I.I., Mel'nichenko G.A., Romantsova T.I. Sindrom giperprolaktinemii. M 2004; 163-176.
  2. Dzeranova L.K., Bykanova N.S., Pigarova E.A. Giperprolaktinemiya i beremennost': osnovnye dostizheniya i nereshennye voprosy. Vestn reprod zdorov'ya 2011; 1: 16-22.
  3. Zhukova E.V., Mel'nichenko G.A., Romantsova T.I., Dzeranova L.K. Beremennost' i rody u bol'nykh s giperprolaktinemicheskim gipogonadizmom. Vestn reprod zdorov'ya 2009; 1: 2-7.
  4. Marova E.I. Neiroendokrinologiya. Yaroslavl' 1999; 201-244.
  5. Barlier A., Jaquet P. Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006; 154: 187-195.
  6. Berinder K., Nystrom T., Hoybye C., Hall K., Hulting A.L. Insulin sensitivity and lipid profile in prolactonomas before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 3: 199-207.
  7. Biller B.M. Hyperprolactinemia. Int J Fertil Womens Med 1999; 44: 74-77.
  8. Bracero N., Zacur H.A. Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am 2001; 28: 77-84.
  9. Can M., Guven B., Atmaca C., Acikgoz S., Mungan G. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia. Kaohsiung J Med Sci 2011; 27: 5: 173-176.
  10. Christin-Maitre S., Delemer B., Touraine P., Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68: 2-3: 106-112.
  11. Dos Santos Silva C.M., Barbosa F., Lima G., Warszawski L., Fontes R., Domingues R., Gadelha M. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011; 19: 4: 800-805.
  12. Gomel V., Munro M.G., Row T.C. Gynecology, a practical approach. Baltimore: Williams and Wilkins 1990; 89.
  13. Ferriman D.M., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol 1961; 21: 1440-1447.
  14. Karunakaran S., Page R.C., Wass J.A. The effect of menopause on prolactin levels in patients with hyperprolactinemia. Clin Endocrinol (Oxford) 2001; 54: 3: 295-300.
  15. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med 2010; 362: 1219-1226.
  16. Lu C.C., Hsieh C.J. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. Kaohsiung J Med Sci 2012; 28: 2: 94-99.
  17. Luciano A.A. Clinical presentation of hyperprolactinemia. J Reprod Med 1999; 44: 2: 1085-1090.
  18. Mah P.M., Webster J. Hyperprolactinemia: Etiology, Diagnosis, and Management. Semin Reprod Med 2002; 20: 4: 365-374.
  19. Maor Y., Berezin M. Hyperprolactinemia in postmenopausal women. Fertil Steril 1997; 67: 4: 693-696.
  20. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003; 112: 1603-1618.
  21. Melmed S., Casanueva F., Hoffman A., Kleinberg D., Montori V., Schlechte J., Wass J. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2011; 96: 2: 273-288.
  22. Molitch M.E. Prolactinomas. The Pituitary. Ed. S. Melmed. Cambridge MA: Blacwell Sci 1995; 443-477.
  23. Ono M., Miki N., Amano K., Kawamata T., Seki T., Makino R., Takano K., Izumi S., Okada Y., Hori T. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metabol 2010; 95: 6: 2672-2679.
  24. Sarno A.D., Landi M.L., Cappabianca P., Salle F.D., Colao A. Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. J Clin Endocrinol Metabol 2001; 86: 11: 5256-5261.
  25. Sieja K., Stanosz S. The concentrations of prolactin and estrogens in women with fibrocystic changes in the breast. Ginekol Pol 2002; 73: 7: 594-599.
  26. St-Jean E., Blain F., Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxford) 1996; 44: 305-309.
  27. Stalldecker G., Mallea-Gil M.S., Guitelman M. et al. Effects of cabergolin on pregnancy and embryo-fetal development: retrospective study of 103 pregnancies and a review of literature. Pituitary 2010; 13: 4: 345-350.
  28. Raymond J.P., Goldstein E., Konopka P., Leleu M.F., Merceron R.E., Loria Y. Follow-up of children born of bromocriptine-treated mothers. Hormon Res 1985; 22: 239-246.
  29. Thorner M.O., Bronstein M. Pituitary Disease and Neuroendocrinology. Eds. A. Grossman. Prolactin Dis 2011; Ch. 6.
  30. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 6: 331: 14: 904-909.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.